Friday, Nov 20, 2026
Export PFE’s income statement to Excel — free account
Pfizer Inc.
PFEHealthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −9.68%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
27.71
0.14
+0.51%
Follow PFE
Alert me
Q3 2026 quarterly report Pfizer described the April 2026 order imposing Section 232 tariffs of up to 100% on imported patented medicines. Read it in the report
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 52,824 | 52,546 | 40,825 | 40,905 | 41,651 | 81,288 | 101,175 | 59,553 | 63,627 | 62,579 | 63,625 | +1.9% | 63,127 | 60,821 | 55,372 | (4.0%) | |
| Gross margin, % | 76.67 | 78.63 | 77.99 | 80.31 | 79.63 | 62.08 | 66.05 | 58.10 | 71.94 | 74.33 | 73.38 | (2.3) pt | ||||||
| EBT | 8,351 | 12,305 | 3,594 | 11,321 | 7,036 | 24,311 | 34,729 | 1,058 | 8,023 | 7,520 | 4,259 | (1.2%) | ||||||
| EBT margin, % | 15.81 | 23.42 | 8.80 | 27.68 | 16.89 | 29.91 | 34.33 | 1.78 | 12.61 | 12.02 | 6.69 | (3.8) pt | ||||||
| Net income | 7,246 | 21,355 | 11,188 | 16,056 | 9,195 | 22,025 | 31,407 | 2,158 | 8,062 | 7,812 | 4,070 | +0.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 8.68 | 8.80 | 6.95 | 7.35 | 7.50 | 14.51 | 18.04 | 10.55 | 11.23 | 11.01 | 11.16 | +2.7% | |||||
| Earnings | 1.17 | 3.57 | 1.90 | 2.92 | 1.73 | 3.92 | 5.59 | 0.38 | 1.42 | 1.37 | 0.71 | +1.8% | ||||||
| Cash flow | 2.66 | 2.81 | 2.70 | 2.26 | 2.59 | 5.82 | 5.22 | 1.54 | 2.25 | 2.06 | 2.49 | (2.8%) | ||||||
| Capex | (0.33) | (0.37) | (0.36) | (0.44) | (0.50) | (0.48) | (0.58) | (0.69) | (0.51) | (0.46) | (0.42) | +3.9% | ||||||
| Free cash flow | 2.33 | 2.44 | 2.33 | 1.82 | 2.10 | 5.33 | 4.64 | 0.85 | 1.74 | 1.60 | 2.07 | (4.1%) | ||||||
| Book value | 9.83 | 12.00 | 10.86 | 11.39 | 11.43 | 13.83 | 17.10 | 15.82 | 15.62 | 15.27 | 15.67 | +5.0% | ||||||
| Shares, m | 6,089 | 5,970 | 5,872 | 5,569 | 5,555 | 5,601 | 5,608 | 5,643 | 5,664 | 5,683 | 5,693 | (0.8%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 27.57 | 9.98 | 22.70 | 13.16 | 21.40 | 15.14 | 9.20 | 82.58 | 18.70 | 18.31 | 38.83 | 23.9 | |||||
| P/S | 3.72 | 4.05 | 6.14 | 5.21 | 4.91 | 4.07 | 2.84 | 2.82 | 2.36 | 2.26 | 2.47 | 3.8 | ||||||
| P/B | 3.28 | 2.97 | 3.93 | 3.36 | 3.22 | 4.27 | 3.00 | 1.88 | 1.70 | 1.63 | 1.76 | 2.9 | ||||||
| EV/Sales | 4.18 | 4.49 | 6.70 | 6.25 | 5.57 | 4.16 | 2.97 | 3.81 | 3.05 | 3.08 | 3.23 | 4.4 | ||||||
| EV/FCF | 15.60 | 16.28 | 19.97 | 25.27 | 20.40 | 11.63 | 11.91 | 56.83 | 21.49 | 23.28 | 18.71 | 22.3 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 16,192 | 16,802 | 15,827 | 12,588 | 14,403 | 32,580 | 29,267 | 8,700 | 12,744 | 11,704 | 14,173 | (3.5%) | |||||
| Capex | (1,999) | (2,217) | (2,136) | (2,464) | (2,765) | (2,711) | (3,236) | (3,907) | (2,909) | (2,629) | (2,387) | +3.1% | ||||||
| Free cash flow | 14,193 | 14,585 | 13,691 | 10,124 | 11,638 | 29,869 | 26,031 | 4,793 | 9,835 | 9,075 | 11,786 | (4.8%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 7,834 | 10,714 | 18,068 | (4,501) | 9,147 | 17,022 | 9,121 | (4,461) | 7,363 | 5,914 | 13,283 | (3.1%) | |||||
| Net debt | 24,236 | 23,499 | 22,907 | 42,504 | 27,613 | 7,367 | 13,097 | 59,198 | 43,874 | 51,199 | 48,399 | +8.7% | ||||||
| Shareholders’ equity | 59,840 | 71,656 | 63,758 | 63,447 | 63,473 | 77,462 | 95,916 | 89,288 | 88,497 | 86,775 | 89,301 | +4.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 4.26 | 12.41 | 6.73 | 9.80 | 5.69 | 13.09 | 16.57 | 1.00 | 3.65 | 3.69 | 1.95 | (0.6) pt | |||||
| ROIC | 9.03 | 9.01 | 4.09 | 3.96 | 5.66 | 14.32 | 20.52 | 0.54 | 5.86 | 6.45 | 6.19 | (2.6) pt | ||||||
| ROE | 11.56 | 32.42 | 16.48 | 25.20 | 14.43 | 31.19 | 36.19 | 2.29 | 9.03 | 8.87 | 4.42 | (2.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 96,500 | 90,200 | 92,400 | 88,300 | 78,500 | 79,000 | 83,000 | 88,000 | 81,000 | 75,000 | — | (2.8%) | |||||
| Revenue/emp, $m | 0.55 | 0.58 | 0.44 | 0.46 | 0.53 | 1.03 | 1.22 | 0.68 | 0.79 | 0.83 | — | +4.8% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| Biopharma | 61,199 | 97.79% |
|---|---|---|
| Other, not broken out | 1,380 | 2.21% |
| Gross margin | 74.33% | |
| Operating margin | 22.76% | |
| Pre-tax margin | 12.02% |
Pfizer Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | |
| NVO Novo Nordisk A/S | $128.6B | 9.8× | — | +3.87% (above 0%: growing) | −17.14% (below 0%: shrinking) | −14.75% (below 0%: shrinking) | 76.97% | 29.06% | Compare |
| BMY Bristol Myers Squibb Company | $119.3B | 12.9× | 12.0× FY26e | +6.93% (above 0%: growing) | −2.78% (below 0%: shrinking) | −35.95% (below 0%: shrinking) | 68.28% | 19.40% | Compare |
| SNY Sanofi | $111.3B | 22.8× | — | +13.89% (above 0%: growing) | +8.21% (above 0%: growing) | +99.60% (above 0%: growing) | 76.16% | 28.53% | Compare |
| GSK GSK PLC Sponsored ADR | $95.9B | 16.4× | 15.5× FY26e | +3.75% (above 0%: growing) | −23.88% (below 0%: shrinking) | +62.44% (above 0%: growing) | 73.11% | 23.93% | Compare |
| Median of peers | $168.2B | 22.8× | 24.0× | +6.77% | −9.96% | −5.99% | 76.08% | 27.80% |
From the latest earnings call
- CEO Albert Bourla said launched and acquired products grew 32% operationally in the quarter, while the legacy Seagen portfolio’s U.S. growth was driven by Padcev.
- CFO Cecile Guegan said Pfizer raised its 2026 revenue and adjusted earnings guidance following non-COVID product growth and progress on cost improvements.
Largest institutional holders 13F, quarter to Jun 30, 2026
Held by institutions
66.78%
Held by the ten largest
34.47%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 552.48m | 9.69% | +6.53m |
| BlackRock | 529.67m | 9.29% | +31.41m |
| State Street | 307.09m | 5.39% | +5.50m |
| Geode Capital Management | 135.28m | 2.37% | +1.71m |
| Fisher Investments | 109.07m | 1.91% | +4.10m |
| Morgan Stanley | 96.35m | 1.69% | +3.66m |
| Norges Bank | 61.51m | 1.08% | +61.51m |
| Northern Trust | 59.08m | 1.04% | −2.94m |
| BNY | 57.88m | 1.02% | +4.00m |
| MFS Investment Management | 56.55m | 0.99% | −360.82k |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Pay and ownership Proxy statement filed Mar 12, 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 27.59m | 33.71m | 86.00 |
| 2024 | 24.65m | 38.52m | 86.00 |
| 2023 | 21.56m | (62.15m) | 88.00 |
| 2022 | 33.02m | 5.66m | 149.00 |
| 2021 | 24.35m | 115.18m | 167.00 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement
Pfizer Inc. (PFE) Latest News
What happened
- Deal Pfizer completed its acquisition of Metsera, adding long-acting injectable obesity drug candidates to its portfolio.
- Legal Arbutus and Genevant filed new lipid nanoparticle patent lawsuits against Pfizer in Japan and added a patent to their Canadian case against Pfizer and BioNTech.
- Capital Pfizer agreed to receive up to $1.5 billion from Blackstone Life Sciences for berobenatide development through 2028, while retaining ownership and control.
- Results Pfizer reported that ELREXFIO improved progression-free survival in a Phase 3 trial, with 68% of patients remaining progression-free at 18 months.
- Guidance Pfizer reported nearly flat third-quarter revenue of $16.6 billion and raised its 2026 revenue outlook to $62 billion–$64 billion.
- Why Did Pfizer Stop Talking Up This Business? Trefis
- Pfizer (PFE) Q3 Earnings Rebuild Confidence As New Drugs Gain Ground Simply Wall St.
- Pfizer Just Raised Guidance. The Bigger Test Comes Next GuruFocus.com
- Pfizer: 3 Key Takeaways for Long-Term Investors The Motley Fool
- Pfizer Inc (PFE) (Q3 2026) Earnings Call Highlights: Raised Guidance, Cost Savings Momentum, ... GuruFocus.com
- Pfizer Q3 Earnings Call Highlights MarketBeat transcript
- Pfizer Inc. Q3 2026 Earnings Call Summary Moby
- Pfizer (PFE) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- Pfizer earnings analysis: questions answered and next catalysts Investing.com
- Pfizer Is Pitched for Its Dividend. The November 3 Report Has to Show Cash Flow Covers It TIKR
10 more headlines
- Can New Products and Acquisitions Revive Pfizer's Growth Story? Zacks
- Pfizer leaps into ‘in vivo’ CAR-T with latest China deal biopharmadive.com +4 reports
- Should You Buy Pfizer Stock For Its Cash? Trefis
- Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions MarketBeat
- Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit? Zacks
- Pfizer's Revenue Barely Moved. Its Forecast Just Went Higher GuruFocus.com
- Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction The Motley Fool
- Pfizer Raises Full-Year Outlook Following Third-Quarter Beat MT Newswires
- PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance Zacks
- Pfizer earnings beat estimates as drugmaker raises 2026 outlook Proactive Investors
PFE metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
Pfizer is a global biopharmaceutical company that researches, develops, manufactures and sells medicines and vaccines. Founded in 1849 and headquartered in New York City, it is led by Chief Executive Officer Albert Bourla.
Its products span several areas of care. Primary care includes the blood thinner Eliquis, migraine treatments Nurtec ODT/Vydura and Zavzpret, and vaccines such as the Prevnar family and Comirnaty. Pfizer also sells Paxlovid for COVID-19. Its specialty medicines address conditions including inflammatory diseases, rare diseases and certain infections.